Laura Chico
Stock Analyst at Wedbush
(1.98)
# 2,870
Out of 4,784 analysts
210
Total ratings
32.62%
Success rate
-7.36%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRML Tourmaline Bio | Maintains: Outperform | $42 → $43 | $16.65 | +158.26% | 2 | Mar 14, 2025 | |
| VIGL Vigil Neuroscience | Maintains: Outperform | $24 → $13 | $1.91 | +580.63% | 9 | Mar 14, 2025 | |
| GOSS Gossamer Bio | Reiterates: Outperform | $4 | $1.17 | +241.88% | 4 | Mar 14, 2025 | |
| OVID Ovid Therapeutics | Maintains: Outperform | $4 → $3 | $0.35 | +757.14% | 2 | Mar 12, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $36 | $19.99 | +80.09% | 6 | Mar 12, 2025 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $27 → $28 | $5.70 | +391.23% | 9 | Mar 12, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $30 → $29 | $24.27 | +19.49% | 14 | Mar 3, 2025 | |
| SAGE Sage Therapeutics | Reiterates: Neutral | $6 | $8.28 | -27.54% | 9 | Feb 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $157 → $147 | $113.16 | +29.90% | 9 | Feb 7, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Neutral | $46 → $48 | $37.82 | +26.92% | 12 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $4.32 | +270.37% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $45 | $23.27 | +93.38% | 9 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $12 | $1.48 | +710.81% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $38 | $26.63 | +42.70% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $4 | $2.27 | +76.21% | 3 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $25 | $19.68 | +27.03% | 9 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $2.35 | +836.17% | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $210 → $205 | $138.37 | +48.15% | 16 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $48 | $38.66 | +24.16% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $34.26 | +43.02% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.65 | +91.78% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $14.78 | +75.91% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.93 | +123.12% | 13 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $14.44 | +190.86% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $7.21 | +135.78% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $41 | $2.53 | +1,520.55% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $31 | $15.80 | +96.20% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.64 | +1,618.48% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $4.21 | +18.76% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $71.44 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $1.93 | +159.07% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $27.65 | +437.07% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $5.52 | +12,943.48% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $22.39 | +1,150.56% | 1 | Apr 21, 2017 |
Tourmaline Bio
Mar 14, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $16.65
Upside: +158.26%
Vigil Neuroscience
Mar 14, 2025
Maintains: Outperform
Price Target: $24 → $13
Current: $1.91
Upside: +580.63%
Gossamer Bio
Mar 14, 2025
Reiterates: Outperform
Price Target: $4
Current: $1.17
Upside: +241.88%
Ovid Therapeutics
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $0.35
Upside: +757.14%
Dianthus Therapeutics
Mar 12, 2025
Reiterates: Outperform
Price Target: $36
Current: $19.99
Upside: +80.09%
Astria Therapeutics
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $5.70
Upside: +391.23%
Apellis Pharmaceuticals
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $24.27
Upside: +19.49%
Sage Therapeutics
Feb 12, 2025
Reiterates: Neutral
Price Target: $6
Current: $8.28
Upside: -27.54%
Neurocrine Biosciences
Feb 7, 2025
Maintains: Outperform
Price Target: $157 → $147
Current: $113.16
Upside: +29.90%
Ultragenyx Pharmaceutical
Jan 13, 2025
Reiterates: Neutral
Price Target: $46 → $48
Current: $37.82
Upside: +26.92%
Dec 13, 2024
Initiates: Outperform
Price Target: $16
Current: $4.32
Upside: +270.37%
Nov 8, 2024
Maintains: Outperform
Price Target: $44 → $45
Current: $23.27
Upside: +93.38%
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $1.48
Upside: +710.81%
Nov 8, 2024
Maintains: Neutral
Price Target: $30 → $38
Current: $26.63
Upside: +42.70%
Oct 23, 2024
Downgrades: Neutral
Price Target: $29 → $4
Current: $2.27
Upside: +76.21%
Oct 9, 2024
Maintains: Outperform
Price Target: $17 → $25
Current: $19.68
Upside: +27.03%
Oct 3, 2024
Initiates: Outperform
Price Target: $22
Current: $2.35
Upside: +836.17%
Sep 23, 2024
Maintains: Neutral
Price Target: $210 → $205
Current: $138.37
Upside: +48.15%
Aug 14, 2024
Maintains: Neutral
Price Target: $40 → $48
Current: $38.66
Upside: +24.16%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $34.26
Upside: +43.02%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.65
Upside: +91.78%
Aug 2, 2024
Maintains: Outperform
Price Target: $30 → $26
Current: $14.78
Upside: +75.91%
Aug 2, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.93
Upside: +123.12%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $14.44
Upside: +190.86%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $7.21
Upside: +135.78%
Jun 6, 2024
Reiterates: Outperform
Price Target: $41
Current: $2.53
Upside: +1,520.55%
May 9, 2024
Maintains: Outperform
Price Target: $35 → $31
Current: $15.80
Upside: +96.20%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.64
Upside: +1,618.48%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $4.21
Upside: +18.76%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $71.44
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $1.93
Upside: +159.07%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $27.65
Upside: +437.07%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $5.52
Upside: +12,943.48%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $22.39
Upside: +1,150.56%